Omnicell Announces Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $308 million, down 1% year over year
- ➤Q3 non-GAAP EPS $0.58, up from $0.51 year over year
- ➤Q3 non-GAAP EBITDA $45 million, up from $41 million year over year
- ➤Full-year 2026 non-GAAP EBITDA guidance raised to $187 million-$193 million
- ➤Full-year 2026 non-GAAP EPS guidance raised to $2.48-$2.56
Expert Statements
Randall A. Lipps, Chairman, chief executive officer, and founder of Omnicell
“We delivered solid third quarter results and continued to execute against our strategic priorities,”
Randall A. Lipps, Chairman, chief executive officer, and founder of Omnicell
“We believe our performance reflects the discipline we have built into the business throughout the year, combined with continued customer interest in solutions that are designed to improve efficiency, safety, and workforce productivity across medication management.”
Randall A. Lipps, Chairman, chief executive officer, and founder of Omnicell
“At the same time, we continue to see strong momentum with our next-generation platform, backed by a growing pipeline,”
Randall A. Lipps, Chairman, chief executive officer, and founder of Omnicell
“Customers are validating the potential value of combining Titan XT with OmniSphere, our cloud-native platform, intended to improve productivity, efficiency, and workflow reliability.”
Randall A. Lipps, Chairman, chief executive officer, and founder of Omnicell
“As we see health systems seek greater visibility and connectivity across the medication-use process, we believe Omnicell Titan XT and OmniSphere position us to capitalize on a significant long-term opportunity we see in autonomous medication management.”
Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” or the “Company”), a healthcare technology leader focused on advancing autonomous medication management, today reported financial results for the third quarter ended September 30, 2026.
Third quarter results reflected continued execution across the business, supported by demand for Omnicell’s connected device portfolio, favorable product and service margins and disciplined cost management. Our business performed well during the quarter, with revenue and profitability both coming in above the high end of our previously provided guidance range, and we continue to see healthcare providers prioritize solutions that are designed to improve operational efficiency, optimize medication workflows, and help address ongoing workforce challenges.
Get started
Create a free account to read the full story.